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Abstract
Background: Spinocerebellar ataxias (SСAs) are a highly heterogeneous group of inherited neurological disorders.
The symptoms of ataxia vary in individual patients and even within the same SCA subtype. A study of a four-
generation family with autosomal dominant (AD) non-progressive SCA with mild symptoms was conducted. The
genotyping of this family revealed no frequent pathogenic mutations. So the objective of this study was to identify
the genetic causes of the disease in this family with the technology of whole-exome sequencing (WES).
Methods and results: WES, candidate variant analysis with further Sanger sequencing, mRNA secondary structure
prediction, and RSCU analysis were performed; a heterozygous missense mutation in ITPR1 was identified.
Conclusion: Our study confirms the fact that ITPR1 gene plays a certain role in the pathogenesis of SCAs, and,
therefore, we suggest that c.4657G>A p.Val1553Met) is a disease-causing mutation in the family studied.
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Background
Spinocerebellar ataxias (SСAs) are a highly heteroge-
neous group of inherited neurological disorders. They
are characterized by significant clinical polymorphism
resulting from combination of cerebellar ataxia with
additional non-cerebellar symptoms, which seriously com-
plicates clinical differentiation [1]. The symptoms of ataxia
vary in individual patients and even within the same SCA
subtype. In general, affected individuals exhibit progres-
sive cerebellar ataxia variably associated with dysarthria,
oculomotor abnormalities, pyramidal and extrapyramidal
signs, epilepsy, and mental impairment. Neuronal loss is
observed predominantly in the cerebellum and the brain-
stem, and neuroimaging (CT or MRI) demonstrates the
atrophy of those regions. These pathologies can be caused
by autosomal dominant (AD), autosomal recessive, and
X-linked mutations.
There are many different SCA classifications based on
both clinical and anatomical principles. Harding suggested
a classification according to the mode of inheritance and
clinical signs [2]. The actual numbering corresponds to
the order of gene description. This molecular classification
is currently the most accepted by the scientific commu-
nity. To date, 38 types of AD SCAs have been identified
[3], which are difficult to distinguish clinically. There are
several common forms of the disease in each geographical
region (such as SCA1, SCA2, SCA3 and some others in
Russia) with dynamic mutations resulting in most severe
clinical manifestations, and these forms are usually diag-
nosed in clinical practice [4]. Other forms of AD SCAs are
rare, occur predominantly in a small number of families,
exhibit relatively mild manifestations, and are difficult to
define because of some phenotypic overlap between them.
Here, a study of a four-generation family with AD
non-progressive SCA with mild symptoms was con-
ducted. The genotyping of this family revealed an ab-
sence of pathogenic mutations that are common for the
Russian population. In such cases for which the screen-
ing of known mutations is negative, whole-exome se-
quencing (WES) can be used in order to find new or
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rare mutations in the coding regions of the genome. We
applied this technology in our family with AD SCA.
Methods
Human subjects
Informed consent was obtained from all participating
patients and families according to the Declaration of
Helsinki, and the studies were approved by the Local
Ethics Committee of the Research Center of Neurology,
Moscow. The pedigree of this family is shown in Fig. 1a.
Peripheral blood was collected and genomic DNA was
isolated from currently available cases (II:2, III:1, III-5,
and IV:1) and two unaffected family members (II:3 and
III:3). The expansion of polyglutamine repeats in SCA1,
SCA2, and SCA3 loci was excluded for all affected mem-
bers of the pedigree. The family under investigation, as
well as the 300 control individuals, were Russians of
Slavonic origin.
Whole-exome sequencing
WES was performed in two affected individuals (II-2
and IV-1) and in unaffected family member (II-3) at the
NGS Core Facility of the Estonian Genome Center, Uni-
versity of Tartu, Estonia. Exome capture was performed
with the TruSeq™ Exome Enrichment Kit (Illumina,
USA), according to the manufacturer’s protocol. The
captured libraries were sequenced with 100-bp paired-end
reads on Illumina platform HiSeq2000. The in-house
pipeline of the Estonian Genome Center, University of
Tartu, was used for the alignment to the reference genome
and variant calling, as described previously [5]. Because
the SCA was an autosomal dominant hereditary disorder
and only one parent was affected, we focused on heterozy-
gous nonsynonymous, frameshift, and canonical splice-
site variants that were absent from public datasets,
including dbSNP137 [6], the 1000 Genomes Project [7],
and the NHLBI Exome Sequencing Project (ESP) Exome
Variant Server database [8]. Variants that were shared by
two affected patients and were absent in a healthy family
member were considered to be potentially related to
the disease. Nonsynonymous amino acid variants were
analyzed using SIFT [9], PolyPhen-2 [10], fathmm
[11], MutationAssessor [12], and MutationTaster [13],
to assess any potentially damaging effects. Protein-
altering SNPs that were predicted to be damaging by
at least two methods were considered as candidate
causative variants. Relevant mutations in all SCA genes
were then prioritized manually.
Validation of selected variants
Candidate variant analysis was performed by Sanger
sequencing of all available family members. PCR primers
for ITPR1 [NG_016144.1], COL6A3 [NG_008676.1],
SCN9A [NG_012798.1], SYNE1 [NG_012855.1], and
COL9A1 [NG_011654.1] variants were designed using
NCBI Primer-BLAST [14] (sequences and PCR conditions
are available upon request). The purification of PCR prod-
ucts was performed using the Axygen Gel Extraction Kit.
Sanger sequencing was performed in both forward and re-
verse directions on an ABI 3730 DNA Analyzer. Se-
quences were analyzed using the Sequence Scanner
Software v.1.0 and AlignX® module for Vector NTI.
Substitution characterization: mRNA secondary structure
prediction and RSCU analysis
The analysis of the secondary structure of the ITPR1
mRNA and of associated Gibbs free energy (ΔG) values
was performed essentially as described previously [15–17].
Gibbs free energy calculation was carried out using the
mfold software [18] based on the nearest neighbor free
Fig. 1 Pedigree and sequence chromatograms of the family. a - Small circles on the top right indicate members for whom whole-exome sequencing
was carried out. Asterisks indicate members for whom the PCR and Sanger sequencing validation were carried out. b - Red letters show
the heterozygous substitution c.4657G>A in the affected individual
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energy model. The RNA structures with the lowest free
energy for a given mRNA fragment (51 nt in length) were
selected and the Gibbs free energy difference (ΔΔG=
mutantΔG – WTΔG) was calculated (with the mutation
of interest positioned in the middle of the mRNA frag-
ment analyzed). It was shown previously that analysis of
short mRNA fragments (~25–75 nt in length) was the
most predictive [15–17].
Calculations of the differences in relative synonymous
codon usage (RSCU) values [19] were carried out as de-
scribed previously [15–17]. Briefly, the RSCU value for a
mutant variant codon and that for the corresponding
WT codon were calculated. ΔRSCU = RSCUmutant –
RSCUwildtype represents a change in the RSCU values
as a consequence of the mutation in the ITPR1 gene and
may be indicative of a change in translation rate around
a particular codon.
Results
Clinical features of the family
The proband, patient A.P. (III-1), was 54 years old and
was delivered normally after an uneventful pregnancy.
The proband initially had some motor delay, began to
walk at the age of 2, and his language and learning devel-
opment was normal. He graduated from high school and
college with satisfactory results. Despite being an agrono-
mist by profession, he is currently employed as a care-
taker. Clinically, for many years he suffered from unsteady
walking, slowness of speech, and abnormal fine motor
skills. The patient noted that some disease -related deteri-
oration had taken place during his adolescence, including
mild memory loss. Marked gait disturbance was observed
at 15 years of age. On examination, he exhibited an un-
steady wide-based gait, especially with his eyes closed,
slightly slurred and slow speech, mild limb ataxia with
intention tremor and dysmetria, mild truncal titubation,
difficulties on tandem walking, and diffuse muscle hypo-
tonia. The total scale for the assessment and rating of
ataxia (SARA) score was 11. He had no nystagmus or par-
esis, and his deep tendon reflexes and sensitivity were nor-
mal. The patient has been under observation for 25 years:
his clinical features were generally stable throughout the
course of the disease, with a very mild increase in gait and
speech difficulties over the last 8–10 years. Cerebral MRI
scans demonstrated mild cerebellar atrophy (Fig. 2). Cogni-
tive examination showed no clinically significant changes
(Montreal cognitive assessment (MoCA) test score was 26).
According to the proband’s evidence, a similar disease
affected his father (II-2) between 15 and 20 years of age.
He had an unsteady gait and scanning speech through-
out his life, but was able to live independently and died
at the age of 81. The proband’s son (IV-1, 27 years of
age) started walking independently only at 3 years of age
and often fell during his childhood. Having graduated
from high school and university with good results, he
pursued studies in hi-tech; now he works successfully as
an IT administrator. He also succeeded in learning a sec-
ond language (English). The patient’s clinical features are
very similar to those of his father, but his gait difficulties
are more severe. The proband’s brother, who is 52 years
old, also suffered from the same disorder and exhibited
similar clinical features starting in adolescence.
Next-generation sequencing (NGS) data
A total of 46507918, 50734956, and 40536854 reads were
obtained for II:2, IV:1 and II:3, respectively. The average
target coverage was 34.0× for II:2, 37.3× IV:1, and 29.0×
for II:3.
Identification of disease-causing mutations
WES identified 947 variants that were heterozygous in
two affected patients and reference homozygous in one
Fig. 2 Cranial MRI of the proband (T2/FLAIR weighted sagittal a, and T2 weighted axial b images) showing mild cerebellar atrophy
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unaffected family member. These heterozygous variants
were filtered through the databases SIFT, PolyPhen-2,
fathmm, MutationAssessor, and MutationTaster; 12
matching variants were found that had a minor allele
frequency (MAF) not exceeding 0.01. Among them,
five variants were nonsynonymous and were predicted
as damaging by at least two prediction methods.
Validation of identified substitution
These five possibly pathogenic variants were analyzed
via PCR and further Sanger sequencing in all available
family members (Table 1). Only the p.Val1553Met
(NM_001099952; NP_001093422) variant was identified
in a heterozygous state in all four affected family members
(II-2, III-1, III-5, and IV-1; see Fig. 1) and in a homozy-
gous (Val1553Val, wild type) state in two healthy individ-
uals (II-3 and III-3) (Fig. 1a, b). This mutation has been
identified once previously in unrelated Australian family
[20]. Next, we evaluated the frequency of the occurrence
of this heterozygous variant in the control population,
which consisted of 300 individuals. All samples analyzed
were homozygous in this position (Val1553Val).
mRNA secondary structure prediction and RSCU analysis
We performed mRNA secondary structure prediction
and RSCU analysis for the p.Val1553Met variant identi-
fied with positive family segregation. Our brief analysis
of the G4684A ITPR1 mutation, which changes a
GUG(Val) codon into an initiator AUG(Met) codon,
showed (Fig. 3) that this mutation led to substantial
changes in Gibbs free energy (ΔG) (ΔΔG = 0.4), as
well as in RSCU (ΔRSCU = –0.85). These changes may be
indicative of a disease-causing mutation [16, 17].
Discussion
As mentioned previously, SCAs represent a heteroge-
neous group of diseases from both the clinical and gen-
etic points of view, as they include forms that are rare
and difficult to diagnose. Therefore, a NGS analysis was
needed to detect the underlying genetic variation. We
performed an analysis of a family with a mild SCA clin-
ical phenotype to identify the genetic variants that may
contribute to the development of disease. One possibly
pathogenic variant, p.Val1553Met, was identified in exon
37 of the ITPR1 gene. We analyzed this mutation in all
family members for whom DNA was available, and in
the Russian population controls. The segregation of the
identified substitution with the disease and its absence
in the control Russian population as well as in the 1000
Genomes Project and the NHLBI ESP Exome Variant
Server database were shown.
Prediction tests for this substitution indicated its
pathogenic significance, as it was predicted as being
probably damaging by PolyPhen-2 and as disease caus-
ing by MutationTaster.
Moreover, a recent genetic data analysis of patients
with hereditary diseases revealed that not only the infor-
mation contained at the amino acid sequence level of
the target protein (mutant vs wild type) but also the in-
formation contained at the mRNA/nucleotide level may
serve as a predictor of disease development and severity
[16, 17]. In the case of blood disorders such as hemophilia
A and B, which are caused by mutations in the f8 and f9
genes, respectively, it has been shown that statistically sig-
nificant differences between severe and nonsevere disease-
causing mutations can be observed at the mRNA level,
i.e., severe disease-causing mutations tend to lead to sub-
stantial changes in the free energy of small mRNA frag-
ments (harboring the site of mutation), and tend to lead
to substantial changes in RSCU values. We evaluated the
stability of the mRNA and the RCSU values for the pos-
sibly pathogenic variant identified, and found that it leads
to a change in the structure and stability of the
mRNA (ΔΔG = 0.4), as well as changes in RSCU
(ΔRSCU = –0.85). Reported data indicate that such
changes may affect the local translation rates, which
can in turn perturb protein folding [21].
Thus, all listed data indicate that the G4684A substitu-
tion identified here, which results in a p.Val1553Met
amino acid change, is disease causing and leads to the
development of a form of SCA with a mild clinical
phenotype in the family studied. This was supported by
the fact that the involvement of ITPR1 gene in the
etiology of SCAs, SCA15 (former SCA16) and SCA29,
was already shown [20, 22–24]. The same substitution
was described previously in an Australian family, and
the authors found another p.N602D substitution in the
ITPR1 gene in a Canadian family [20]. The neurological
Table 1 Summary of variants revealed by whole-exome sequencing in the patients with SCA
Gene SNP ID Nucleotide/protein Prediction by
SIFT PolyPhen2 MutationTaster MutationAssessor fathmm
ITPR1 rs397514535 c.4657G>A p.Val1553Met Tolerated Probably damaging Disease causing Predicted non-functional (low) Tolerated
COL6A3 rs146092501 c.4156G>A p.Glu1386Lys Tolerated Possibly damaging Polymorphism Predicted non-functional (low) Damaging
SCN9A rs41268673 c.1828C>A p.Pro610Thr Tolerated Benign Disease causing Predicted functional (medium) Damaging
SYNE1 rs138787771 c.23315G>A p.Arg7772Gln Tolerated Benign Disease causing Predicted functional (medium) Tolerated
COL9A1 rs77706858 c.1349A>G p.Glu450Gly Tolerated Probably damaging Disease causing Predicted non-functional (low) Damaging
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syndrome in the Canadian and Australian families was
similar, with obvious anticipation and very slow clinical
deterioration over many years. The lack of cognitive re-
tardation in childhood and adolescence and the lack of
clinically significant cognitive impairment in adulthood
were important differences between our case and those
occurring in the Australian and Canadian families.
To date, little is known about the role of the ITPR1
gene in the pathogenesis of SCAs; however, we know
that it encodes the type 1 inositol 1,4,5-trisphosphate
(IP3) receptor, which is an intracellular IP3-gated calcium
channel that modulates intracellular calcium signaling
[25]. It releases calcium from the endoplasmic reticulum
by binding to specific receptors that are coupled to cal-
cium channels. These receptors are abundant in neur-
onal and non-neuronal tissues. Val1553 is located within
the binding domain for carbonic anhydrase VIII (CA8).
Its precise function is unknown, but it is assumed that
CA8 competes with IP3 for binding to IP3R and inhibits
the release of Ca from cells. It was supposed that the
p.Val1553Met affects the cellular homeostasis of calcium,
which is important for neuronal cells [26]. In addition,
there is evidence of a direct physical interaction between
ITPR1 and VCP proteins [27]. This protein is involved in
the processes of neurodegeneration: mutations in VCP
cause a pleiotropic degenerative disorder called multi-
system proteinopathy, which can manifest clinically as
classical amyotrophic lateral sclerosis, frontotemporal de-
mentia, inclusion body myopathy, or a combination of
these disorders [28, 29]. Furthermore, VCP interacts dir-
ectly with ATXN3, which plays an important role in the
pathogenesis of SCAs [17, 18]. Therefore, we can assume
that changes in the amino acid structure of ITPR1 may in-
directly affect the activity of VCP or ATXN3, which may
contribute to the development of a neurodegenerative
process in this type of ataxia.
Conclusions
Thus, all existing data on the ITPR1 genetic variation al-
lows to presume that this gene plays an important role
in the pathogenesis of SCAs, and, therefore, we suggest
that the p.Val1553Met variant is a disease-causing muta-
tion in the family studied.
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